OTC Markets OTCPK - Delayed Quote USD

Rohto Pharmaceutical Co.,Ltd. (RPHCF)

Compare
21.54
0.00
(0.00%)
As of December 25 at 3:00:00 PM EST. Market Open.
Currency in JPY All numbers in thousands
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
270,840,000.00
270,840,000.00
238,664,000.00
199,646,000.00
181,053,000.00
Cost of Revenue
113,554,000.00
113,554,000.00
101,243,000.00
83,476,000.00
74,326,000.00
Gross Profit
157,285,000.00
157,285,000.00
137,421,000.00
116,170,000.00
106,726,000.00
Operating Expense
117,233,000.00
117,233,000.00
103,457,000.00
87,151,000.00
83,732,000.00
Operating Income
40,052,000.00
40,052,000.00
33,964,000.00
29,019,000.00
22,994,000.00
Net Non Operating Interest Income Expense
1,327,000.00
1,327,000.00
715,000.00
120,000.00
196,000.00
Pretax Income
41,518,000.00
41,518,000.00
34,290,000.00
27,874,000.00
23,006,000.00
Tax Provision
10,123,000.00
10,123,000.00
7,860,000.00
6,686,000.00
6,236,000.00
Net Income Common Stockholders
30,936,000.00
30,936,000.00
26,377,000.00
21,127,000.00
16,743,000.00
Diluted NI Available to Com Stockholders
30,936,000.00
30,936,000.00
26,377,000.00
21,127,000.00
16,743,000.00
Basic EPS
135.61
--
115.62
92.61
73.39
Diluted EPS
135.21
--
115.29
92.34
73.18
Basic Average Shares
228,124.77
--
228,139.00
228,140.00
228,140.00
Diluted Average Shares
228,799.65
--
228,788.27
228,795.76
228,792.02
Total Operating Income as Reported
40,048,000.00
40,048,000.00
33,959,000.00
29,015,000.00
22,990,000.00
Total Expenses
230,787,000.00
230,787,000.00
204,700,000.00
170,627,000.00
158,058,000.00
Net Income from Continuing & Discontinued Operation
30,936,000.00
30,936,000.00
26,377,000.00
21,127,000.00
16,743,000.00
Normalized Income
31,695,780.00
31,695,780.00
27,119,473.00
22,667,495.00
18,146,325.00
Interest Income
1,523,000.00
1,523,000.00
962,000.00
368,000.00
341,000.00
Interest Expense
196,000.00
196,000.00
247,000.00
248,000.00
145,000.00
Net Interest Income
1,327,000.00
1,327,000.00
715,000.00
120,000.00
196,000.00
EBIT
41,714,000.00
41,714,000.00
34,537,000.00
28,122,000.00
23,151,000.00
EBITDA
50,401,000.00
50,401,000.00
42,338,000.00
35,811,000.00
29,899,000.00
Reconciled Cost of Revenue
113,554,000.00
113,554,000.00
101,243,000.00
83,476,000.00
74,326,000.00
Reconciled Depreciation
8,687,000.00
8,687,000.00
7,801,000.00
7,689,000.00
6,748,000.00
Net Income from Continuing Operation Net Minority Interest
30,936,000.00
30,936,000.00
26,377,000.00
21,127,000.00
16,743,000.00
Total Unusual Items Excluding Goodwill
-1,005,000.00
-1,005,000.00
-963,000.00
-2,035,000.00
-1,925,000.00
Total Unusual Items
-1,005,000.00
-1,005,000.00
-963,000.00
-2,035,000.00
-1,925,000.00
Normalized EBITDA
51,406,000.00
51,406,000.00
43,301,000.00
37,846,000.00
31,824,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-245,220.00
-245,220.00
-220,527.00
-494,505.00
-521,675.00
3/31/2021 - 3/10/2010

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade